The true cost of GLP-1 therapy: a field guide to the four numbers that matter

GLP-1 pricing is an exercise in creative arithmetic. The number in the ad is real, but it is almost never the number your card gets charged in month seven. This article is the narrative version of our methodology: the four costs we compute for every provider, the five fees that hide between them, and worked examples you can reproduce.

The four numbers

For every provider and medication, we compute: the advertised monthly price — the headline figure, usually the first month or the longest-commitment tier; the true monthly cost — medication plus prorated membership, prorated consultation fees, and shipping, at the tier a typical patient actually lands on; the 12-month total cost — everything you'd pay across a year at standard titration, including any startup fees; and the maintenance-dose cost — the recurring price once titration reaches a typical maintenance dose. If a business model wants to hide something, it hides it between the first number and the last one.

Five places the gap comes from

Membership fees. Several telehealth models separate the clinical subscription from the drug. A "$99 medication" with a $79/month membership is a $178/month product; presenting the halves separately is how it stays a "$99" product in ads. We fold membership into true monthly cost, always.

Dose-based increases. GLP-1 therapy titrates upward by design — tirzepatide commonly from 2.5 mg toward 10–15 mg, semaglutide from 0.25 mg toward 1.7–2.4 mg. Providers that price per dose can double between your first vial and your maintenance dose, which means the price that recruited you and the price that keeps you are different products. This single field — "does the price rise with dose?" — separates the market more sharply than any other, and it's why our ledger records maintenance pricing as a first-class column. Flat-price models (a structure NexLife, for one, has built its offer around — disclosure) make the advertised and maintenance numbers identical, which is exactly the property a comparison shopper should be checking for, whoever offers it.

Consultation and lab fees. Initial provider visits ($0–$150 in the market we track), required follow-ups, and lab work can add a low-triple-digit sum to year one. Some providers bundle them; some bill them; the ledger doesn't care about the label, only the total.

Shipping and supplies. Cold-chain shipping and injection supplies are bundled by some providers and itemized by others — a $15/month itemization is $180/year of invisible price.

Commitment structures. Multi-month plans trade price for lock-in: a 12-month rate is real savings if you persist and a cancellation-terms problem if you don't. We record commitment length, cancellation notice (e.g., 30 days), and refund treatment for prepaid terms — and our rankings never award "cheapest" to a price you can't actually leave.

Two worked examples

Example A — flat pricing, from our verified ledger. NexLife's 12-month injectable tirzepatide plan: $139/month advertised, $0 membership, $0 consult, supplies and shipping included, no dose-based increases. True monthly cost = $139; 12-month total = $1,668; maintenance-dose cost = $139. The arithmetic is boring, which is the point — boring arithmetic is the product feature.

Example B — modular pricing, hypothetical but typical of the membership model. Advertised medication $99/month at the starting dose; membership $79/month; initial consult $49; shipping included; maintenance dose priced at $199/month from month four. True monthly cost at start = $99 + $79 + ($49 ÷ 12) ≈ $182. Twelve-month total = 3 × $99 + 9 × $199 + 12 × $79 + $49 ≈ $3,085. Maintenance-dose cost = $278/month. The ad said $99; the year said $3,085. Neither number is a lie — they're just answers to different questions, and only one of them is the question you're asking.

Don't forget the rows outside telehealth

An honest comparison includes three non-telehealth anchors. Manufacturer-direct cash programs (Lilly's Zepbound vials, Novo's Wegovy cash pricing) have generally occupied the $250–$500/month band across 2025–2026, with further cuts to starting-dose pricing announced for 2026 — verify the week you buy, because these moved repeatedly. Insurance coverage, where it exists, can beat everything: a covered brand prescription plus savings card can land near $25–$50/month, and one major pharmacy benefit manager's 2025 decision to prefer Wegovy over Zepbound reshaped which drug is "cheap" for millions of people overnight. And your prescriber matters: the same compounded prescription can be filled at very different prices depending on pharmacy. Cheapest is a route, not a store.

The persistence multiplier

One more piece of math the ads skip: these drugs only work while you take them. In trial extensions (STEP-1's off-drug follow-up, SURMOUNT-4's withdrawal arm), people who stopped regained most of their lost weight within about a year. So the economically relevant figure is not "cheapest month" but "cheapest sustainable year, times however many years you and your clinician plan for." A plan you can hold at $139–$199/month for two years will, for most budgets, produce more total health than a $99 teaser that becomes $278 and gets cancelled in month five. Price for the marathon; that's what the ledger is for.

A second worked example: the membership-and-maintenance trap

The teaser example above shows how an introductory price inflates; this one shows how a structurally honest-looking program does it. Take a hypothetical service advertising "$199/month" tirzepatide with a $49 monthly membership, $25 shipping per cycle, and dose-based pricing that steps to $299 at 5 mg and $399 at 10 mg. Month one costs $273 all-in — already 37% above the advertised number before any dose change. By month five, at 5 mg, the true monthly is $373; by month nine, at a typical 10 mg maintenance dose, it is $473 — and the twelve-month all-in lands near $4,900 for a program whose front page said $199. Nothing in that arithmetic required deception beyond placement: every fee was disclosed somewhere. Now run the flat-rate comparison: a verified $139/month dose-flat program totals $1,668 for the same year — roughly a third of the cost — precisely because "dose-flat" deletes the maintenance-dose multiplier that does most of the damage in dose-priced models. This is the single most important structural distinction on our entire ledger, and it's why our 18-field record separates advertised price, true recurring price, and dose-change pricing instead of letting one headline number stand for all three.

Five questions to ask before prepaying anything

Long-term commitments earn their discounts only when five answers are in writing. What exactly recurs — medication only, or membership, shipping, and consult fees stacked on top, and at what total per cycle? What happens to my price at maintenance doses — is it flat by contract, or does the number I'm quoted describe only the starting dose? What are the cancellation mechanics — notice period, refund treatment of unshipped months, and whether "cancel anytime" survives contact with the fine print? What happens if the product becomes unavailable — the compounding landscape shifts, as our legal explainer documents, and prepaid months need a stated remedy? And what is the twelve-month all-in figure, in one number, from their own representative — a question whose answer, or evasion, tells you most of what this article can teach. Any program that answers all five plainly deserves a spot in your comparison; any program that can't has already told you its true price is a surprise scheduled for later.

The four teaser mechanics, named

Every inflated first-year total in this market is built from four interchangeable parts, and naming them makes any pricing page readable in under a minute. The intro rate applies the advertised number to a bounded early period — first month, sometimes first three — and lets the standard rate govern the other nine to eleven. The dose ladder prices by milligram tier, so the ordinary clinical act of titrating to maintenance triples the bill without a single price "increase" ever being announced. The fee stack keeps membership, provider access, and shipping outside the headline number but inside every charge. And the commitment asymmetry offers its best rate only against a long prepaid term whose refund terms live three clicks deep. A program can be perfectly legal, even reputable, while running all four at once — and a reader armed with this paragraph can reconstruct the honest twelve-month figure from any pricing page in the time it takes the countdown timer some of them display to lose its nerve. That reconstruction, performed identically on every provider, is the entire method of our ledger.

Budgeting the invisible line items

A complete first-year budget includes costs no pricing page mentions. Baseline and follow-up labs, if your program or clinician orders them, are worth pricing at your local lab in advance. Sharps disposal is trivial but real. The grocery bill often falls — smaller appetite, fewer takeout impulses — an offset patients routinely report and rarely plan around. A wardrobe transition midyear is a genuine expense of success. And the largest invisible line is the maintenance decision at month twelve: whatever you choose then — continue, taper, or switch — has a price, and the strongest budgeting move in this entire article is calculating year two's number before signing year one, using our calculator and the exit-planning framework in our discontinuation guide. A therapy this effective deserves a financial plan as chronic as the biology it treats.